Abstract 128P
Background
Immune checkpoint inhibitors (ICI) have opened a new era in the clinical management of hepatocellular carcinoma (HCC). Unfortunately, not all patients benefit from this treatment. Nucleic acid-based therapies, particularly those utilizing lipid nanoparticles (LNPs) as delivery vehicles, offer promising avenues for cancer treatment. In this study, we hypothesized that intracellular delivery of non-coding double-stranded DNA (dsDNA) by LNPs can activate the innate system to induce antitumor immune responses and potentiate ICI.
Methods
Non-coding DNA-LNPs were formulated by mixing promoterless plasmid and lipid components using a microfluidic device. Their antitumor efficacy, alone or in combination with anti-PD-L1 antibodies, was interrogated in genetically and chemically induced mouse models of HCC. Cytokine levels in serum were measured 4 hours post-treatment. At the study endpoint, livers were harvested for macroscopic evaluation, immunohistochemistry staining, and gene expression analysis. Survival was also analyzed.
Results
Administration of non-coding DNA-LNPs in mice induced a rapid and dose-dependent elevation in serum cytokines including IFN-γ, TNF-α, IL-6 or IFN-β. This immune activation led to the recruitment of endogenous CD8+ T cells, which mediated a significant antitumor effect as indicated by increased overall survival and reduced liver/body weight ratio and tumor nodule count. Depletion of CD8+ T cells abrogated therapeutic efficacy. Neither cytokine elevation nor antitumor effects were observed after treatment with empty LNPs, suggesting that these responses were triggered by the activation of cytosolic DNA-sensing pathways. Combining DNA-LNPs with anti-PD-L1 antibodies showed a synergistic effect, with 90% of mice remaining disease-free at the endpoint as compared to 20% and 50%, respectively, with either treatment alone.
Conclusions
Non-coding DNA-LNPs represent a promising therapeutic strategy for HCC, capable of eliciting potent antitumor immune responses. Their efficacy, particularly in combination with ICI, highlights their potential for clinical application in treating HCC.
Legal entity responsible for the study
Spark Therapeutic Inc.
Funding
Spark Therapeutics.
Disclosure
S. Yum, M. Walsh, P. Cejas, S. Armour: Financial Interests, Personal, Full or part-time Employment: Spark Therapeutics Inc.; Financial Interests, Personal, Licencing Fees or royalty for IP: Spark Therapeutics Inc.; Financial Interests, Personal, Stocks/Shares: Spark Therapeutics Inc. R. Zhang: Financial Interests, Personal, Licencing Fees or royalty for IP: Spark Therapeutics Inc. X.M. Anguela: Financial Interests, Personal, Licencing Fees or royalty for IP: Spark Therapeutics Inc. A. Nahvi: Financial Interests, Personal, Licencing Fees or royalty for IP: Spark Therapeutics Inc. S. Guedan: Financial Interests, Personal, Licencing Fees or royalty for IP: IDIBAPS. All other authors have declared no conflicts of interest.
Resources from the same session
7P - ACOX2 disturbs the stability of MRE11-RAD50-NBS1 complex and shapes activated immune tumor microenvironment in clear cell renal cell carcinoma
Presenter: Shiqi Ye
Session: Poster Display session
Resources:
Abstract
9P - CXCR6+PD-1- Tissue Resident memory T cells are associated with poor prognosis in patients with metastatic colorectal cancer
Presenter: Emilien Laloy
Session: Poster Display session
Resources:
Abstract
10P - Tumor-infiltrating lymphocytes and tertiary lymphoid structures in oral cavity squamous cell carcinoma in non-smokers and non-drinkers: Predict clinical outcome
Presenter: Israa Laklouk
Session: Poster Display session
Resources:
Abstract
11P - Tumor-infiltrating lymphocytes on routine H&E staining with automated quantification predict outcomes in resectable non-small cell lung cancer
Presenter: Guus Heuvel
Session: Poster Display session
Resources:
Abstract
12P - Epithelial-mesenchymal transition facilitates response to AXL/PD-1 inhibition in relapsed mesothelioma
Presenter: Essa Baitei
Session: Poster Display session
Resources:
Abstract
14P - Integrated genomic analysis of whole genomes to derive a biomarker of durable response to immunotherapy in melanoma
Presenter: Irene Lobon
Session: Poster Display session
Resources:
Abstract
15P - Verteporfin might potentiate the effects of anti-PD-1 therapy in melanoma-bearing mice model
Presenter: Szonja Kovács
Session: Poster Display session
Resources:
Abstract
16P - Immune checkpoint blockade and HLA-related epistasis in melanoma: Genetic determinants of response and toxicity
Presenter: Martin Little
Session: Poster Display session
Resources:
Abstract
17P - Identification PD-L1-associated lncRNA biomarkers for immunoregulation in ovarian cancer
Presenter: Hee Jung Kim
Session: Poster Display session
Resources:
Abstract
19P - Genetic profiling of early triple-negative breast cancer patients with an indication for neoadjuvant pembrolizumab
Presenter: Bogdan Popescu
Session: Poster Display session
Resources:
Abstract